Cerity Partners LLC Acquires 10,625 Shares of Boston Scientific Corporation $BSX

Cerity Partners LLC boosted its holdings in Boston Scientific Corporation (NYSE:BSX) by 0.8% during the second quarter, Holdings Channel.com reports. The fund owned 1,301,504 shares of the medical equipment provider’s stock after buying an additional 10,625 shares during the quarter. Cerity Partners LLC’s holdings in Boston Scientific were worth $139,794,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the business. Norges Bank purchased a new stake in Boston Scientific in the second quarter valued at approximately $2,089,937,000. Edgewood Management LLC purchased a new position in Boston Scientific in the 2nd quarter worth approximately $746,655,000. Bessemer Group Inc. increased its holdings in shares of Boston Scientific by 14,391.8% in the 2nd quarter. Bessemer Group Inc. now owns 2,919,801 shares of the medical equipment provider’s stock worth $313,618,000 after buying an additional 2,899,653 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Boston Scientific by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider’s stock valued at $14,729,575,000 after buying an additional 2,545,381 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in Boston Scientific by 18.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider’s stock worth $1,070,387,000 after acquiring an additional 1,664,108 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Performance

Shares of BSX stock opened at $97.46 on Friday. The company has a market capitalization of $144.48 billion, a P/E ratio of 52.12, a PEG ratio of 1.96 and a beta of 0.67. Boston Scientific Corporation has a fifty-two week low of $85.98 and a fifty-two week high of $109.50. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. The stock has a 50 day moving average price of $99.27 and a two-hundred day moving average price of $102.04.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The firm had revenue of $5.07 billion for the quarter, compared to analysts’ expectations of $4.97 billion. During the same quarter last year, the business earned $0.63 earnings per share. The business’s revenue was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Buying and Selling at Boston Scientific

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the transaction, the executive vice president owned 178,342 shares in the company, valued at $17,739,678.74. The trade was a 21.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Ellen M. Zane sold 12,891 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total value of $1,266,927.48. Following the transaction, the director directly owned 24,134 shares of the company’s stock, valued at $2,371,889.52. The trade was a 34.82% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 143,095 shares of company stock worth $14,228,950. 0.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research firms have weighed in on BSX. Morgan Stanley raised their price target on Boston Scientific from $125.00 to $130.00 and gave the company an “overweight” rating in a research report on Thursday, October 23rd. Leerink Partners raised their price objective on Boston Scientific from $127.00 to $128.00 and gave the company an “outperform” rating in a report on Wednesday, October 1st. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $124.00 target price on shares of Boston Scientific in a research note on Wednesday, October 22nd. Truist Financial lifted their price target on shares of Boston Scientific from $129.00 to $130.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Finally, Wells Fargo & Company upped their price objective on shares of Boston Scientific from $124.00 to $125.00 and gave the company an “overweight” rating in a research note on Thursday, October 23rd. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $123.77.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.